Plus Therapeutics director awarded options, RSUs
Plus Therapeutics director Richard J. Hawkins received new equity awards on May 14, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Plus Therapeutics director Richard J. Hawkins received new equity awards on May 14, 2026. He was granted stock options for 3,686 shares of common stock at an exercise price of $5.76 per share, expiring on May 14, 2036. He also received 3,686 Restricted Stock Units, each representing one share of common stock.
The RSUs vest in four equal quarterly installments starting on July 1, 2026. The options vest in substantially equal monthly increments over 12 months, and are scheduled to be fully vested at the company’s 2027 Annual Stockholder Meeting, subject to his continued service.
Insider Trade Summary
Grant/Award: 7,372 shares
Grant/Award
2 txns
Insider
Hawkins Richard J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 3,686 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 3,686 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 3,686 contracts (Direct);
Stock Option (Right to Buy) — 3,686 contracts (Direct)
Footnotes (2)
- F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
- F2. The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.
Key Figures
Stock options granted: 3,686 options
Option exercise price: $5.76 per share
Option expiration: May 14, 2036
+3 more
6 metrics
Stock options granted
3,686 options
Granted May 14, 2026 to director Richard J. Hawkins
Option exercise price
$5.76 per share
Exercise price for 3,686 stock options
Option expiration
May 14, 2036
Expiration date of Hawkins’ stock options
RSUs granted
3,686 RSUs
Restricted Stock Units tied to common stock
RSU vest start
July 1, 2026
First vesting date for RSUs, 1/4 of the award
Option vest completion target
2027 Annual Stockholder Meeting
Options scheduled to vest in full by this meeting
Key Terms
Restricted Stock Units, Stock Option (Right to Buy), vest ratably, exercise price
4 terms
Restricted Stock Units financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with an exercise price of 5.7600."
vest ratably financial
"The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments."
exercise price financial
"conversion_or_exercise_price: "5.7600" per share for the stock options."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Plus Therapeutics (PSTV) director Richard J. Hawkins receive in this Form 4?
Richard J. Hawkins received equity compensation awards, including stock options and Restricted Stock Units. The filing shows 3,686 stock options and 3,686 RSUs tied to Plus Therapeutics common stock, reflecting routine director compensation rather than open-market share purchases or sales.
How many Plus Therapeutics (PSTV) stock options were granted to Richard J. Hawkins?
He was granted options covering 3,686 shares of Plus Therapeutics common stock. These options carry an exercise price of $5.76 per share and expire on May 14, 2036, representing compensation rather than a cash purchase of shares in the open market.
What are the terms of the Restricted Stock Units granted to the Plus Therapeutics (PSTV) director?
Hawkins received 3,686 Restricted Stock Units, each representing a right to one share of common stock. The RSUs vest ratably in four equal quarterly installments, starting on July 1, 2026, and continue vesting each quarter thereafter, subject to his continued service.
How do the new Plus Therapeutics (PSTV) stock options for Richard J. Hawkins vest?
The options vest monthly over 12 months from the May 14, 2026 grant date. They are scheduled to be fully vested at Plus Therapeutics’ 2027 Annual Stockholder Meeting, provided Hawkins continues serving the company through each vesting date or that annual meeting.
Does this Plus Therapeutics (PSTV) Form 4 show any open-market stock purchases or sales?
No open-market buys or sells are reported. The Form 4 only shows grant or award acquisitions of stock options and Restricted Stock Units for director Richard J. Hawkins, which are compensation-related equity awards rather than discretionary market transactions in PSTV shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
